Saturday 17 October 2026
Export NRSN’s income statement to Excel — free account
NeuroSense Therapeutics Ltd.
NRSN Healthcare Biotechnology
Insiders bought in the last twelve months.
3.07
0.10
−3.15%
Follow NRSN
| Jun '26 | Jun '25 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | — | 0.00 | |
Free Cash Flow |
— | (10.51) | — | (6.87) | |
Capital Expenditures |
— | (0.06) | — | (0.07) | |
| Other line items | |||||
Cash ROIC |
0.00% | (5,530.53%) | 0.00% | 1,621.46% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Operating CF/Net income |
— | 0.00 | — | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.35 | 0.00 | 0.18 | |
Capex/Depreciation |
— | (2.86) | — | (5.36) | |
Operating CF per Share |
— | 0.00 | — | 0.00 | |
Capex per Share |
— | 0.00 | — | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026